David Blank

David Blank

Arnall Golden Gregory LLP

Contact
View Bio
RSS

Latest Posts › Department of Justice (DOJ)

Share:

Narrowing FCA Cases Based on Kickback Allegations: What Healthcare and Life Sciences Companies Need to Know About the Regeneron...

On February 18, 2025, in a closely watched decision, the United States Court of Appeals for the First Circuit in United States v. Regeneron Pharmaceuticals Inc., No. 23-2086, 2025 U.S. App. LEXIS 3667 (1st Cir. Feb. 18, 2025)...more

2/24/2025  /  Anti-Kickback Statute , Appellate Courts , Department of Justice (DOJ) , Enforcement Actions , False Claims Act (FCA) , Fraud , Life Sciences , Medicare , Pharmaceutical Industry , Whistleblowers
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide